Partenariat

Articles

• Vect-Horus announces the signing of a scientific collaboration agreement with SERVIER
  28 January 2019, by Jonathan NOWAK

  The two companies intend to enter in a collaboration agreement to develop new therapeutic molecules in the field of central nervous system (CNS) diseases
  VECT-HORUS, a biotechnology company that designs and develops peptide vectors that facilitate the delivery of drugs or imaging agents, notably in the brain, is announcing today the signing of a scientific collaboration agreement with SERVIER. The companies did not disclose the financial terms of this agreement. This collaboration is part (…)

• Vect-Horus announces the signing of a scientific collaboration agreement with SANOFI in the field of neurodegenerative diseases
  28 January 2019, by Jonathan NOWAK

  The goal of this collaboration is to use VECT-HORUS’ proprietary technology to transport therapeutic antibodies into the brain for the treatment of a neurodegenerative disease.

• Vect-Horus enters into Collaboration and License Agreement with ONO Pharmaceutical Co., Ltd.
  26 March 2019, by Jonathan NOWAK

  Vect-Horus S.A.S. announced today the signing of a collaboration and license agreement with Ono Pharmaceutical Co., Ltd., focused on the development of novel molecules targeting neurodegenerative diseases

• Vect-Horus, AAA form scientific collaboration to open new avenues in treatment of brain diseases
  28 January 2019, by Jonathan NOWAK

  The partnership will develop new molecules for the treatment of brain diseases
  Vect-Horus, a French company specialized in the development of vector molecules for the central nervous system, announces today it has signed a scientific collaboration agreement with Advanced Accelerator Applications (AAA), a fast growing international player in Molecular Nuclear Medicine (MNM). The financial terms of the deal have not been disclosed.
  This agreement is part of Vect-Horus’ strategy to leverage (…)

• Vect-Horus and Cerimed announce collaboration to support the development of its theragnostic agents
  17 November 2020, by Elodie DORMES

  Vect-Horus is co-developing with Radiomedix one agent which will enter clinical trials in 2021 for the diagnosis of glioblastoma.
  With Cerimed, Vect-Horus also pursues the investigations on its other theragnostic candidates targeting the Low-Density Lipoprotein Receptor, which has been shown to be expressed at high levels in some tumours, including pancreatic tumours.

• Vect-Horus is a partner laureate of the ANR MALZ 2010 call for proposals
  28 January 2019, by Jonathan NOWAK

  VECT-HORUS is a partner laureate of the Agence Nationale de la Recherche (ANR) MALZ 2010 call for proposals and will be involved in the ADHOC project coordinated by the UMR7259 laboratory (Coordinator, Pr. François Féron).
  This project received support (label) from the EUROBIOMED Biocluster.

• Vect-Horus is a partner laureate of the ANR MALZ 2011 call for proposals
  28 January 2019, by Jonathan NOWAK

  VECT-HORUS is a partner laureate of the Agence Nationale de la Recherche (ANR) MALZ 2011 call for proposals and will be involved in the PREVENTAD project coordinated by the UMR7259 laboratory (Coordinator, Dr. Michel Khrestchatisky).
  This project received support (label) from the EUROBIOMED Biocluster.
  VECT-HORUS recruits to reinforce its in vitro BBB model platform.

• Vect-Horus announces Collaboration and Option Agreement with ASTELLAS Pharma
  4 June 2019, by Jonathan NOWAK

  Vect-Horus announced today the signing of the Research Collaboration and Option Agreement (the “Agreement”) with Astellas Pharma Inc., a Japan based pharmaceutical company (“Astellas”). Vect-Horus will use its proprietary technology VECTrans® to transport Astellas’ antibody to the brain for the treatment of CNS diseases.

• Vect-Horus is a partner laureate of the ANR RPIB Call 2013 for proposals
  28 January 2019, by Jonathan NOWAK

  VECT-HORUS is a partner laureate of the Agence Nationale de la Recherche (ANR) RPIB Call 2013 for proposals and will be involved in the VEC2Brain project involving 3 academic laboratories. The project will be coordinated by Dr Michel Khrestchatisky, Director of the UMR7259 laboratory (CNRS and Aix-Marseille University) and involves the U705 laboratory (Director, Pr. Jean-Michel Scherrmann) of INSERM and the SIMOPRO laboratory (Director Dr. Vincent Dive) of the CEA. This project received (…)

• Relocation of the company to support its development
  1 October 2019, by Elodie DORMES

  Relocation of Vect-Horus in medical faculty of the La Timone campus to maintain strong collaborative working environment with its historical partners and support its development.